Dr. Chizu Saeki, Founder & CEO of SONoALS

Transforming ALS Diagnosis and Drug Discovery

Breakthrough diagnosis and treatments
—reimagining ALS care with cutting-edge technology.

About SONoALS

Mission-Driven Science

SONoALS, Inc. is a pioneering startup to redefine how ALS is diagnosed and treated. Our mission is to bring non-invasive, data-rich monitoring to the frontlines of neurodegenerative disease research. The team unites clinical neuroscience and biomedical engineering to make that mission a reality.

Breakthrough Technology

Wearable Ultrasound × AI-Powered Analysis

Revolutionary ultrasound technology combined with AI-powered analysis for Amyotrophic Lateral Sclerosis (ALS) monitoring and diagnosis.

Precision Tools for ALS Research and Beyond

Transforming healthcare through innovative applications in early diagnosis and drug discovery.

Applications

Early and Non-invasive Diagnosis of ALS

Fasciculations are one of the biomarkers that appear earlier than needle EMG abnormalities.

Drug Discovery Support

Fasciculation biomarkers responding in days

Pre-clinical drug screening in humans
Selection of responder groups
Significant reduction in clinical trial duration
Personalized medicine

We aim to realize these goals.

News & Press

Latest updates and achievements from SONoALS

Wearable Ultrasound Device Prototype Completed

Connectable to a laptop for simultaneous 4-muscle patch measurement, capable of recording high-quality ultrasound video for 20 minutes

Presented at the Industry-Government-Academia Innovation School hosted by the Japanese Society of Neurology

Feb 26, 2026

CEO Saeki presented at the Seeds Development Presentation to an audience of 350

Lecture at Computational Neurology Club (CNC)

Feb 10, 2026

CEO Saeki delivered a 90-minute lecture at the 22nd Computational Neurology Club (CNC)

Get in Touch

Ready to learn more about our revolutionary ALS technology? Let's connect.

Chizu Saeki, MD, Ph.D.

Founder & CEO, SONoALS

LinkedIn Profile

Tadashi Kojima

COO, SONoALS